Octapharma USA, Inc.
Octapharma is a global healthcare company focused on development and manufacture of human protein therapies sourced from human plasma and human cell lines. The company operates plasma collection centers, conducts preclinical and clinical research across hematology, immunotherapy and critical care, and supplies plasma‑derived and cell‑line produced biologics alongside ancillary materials for industrial customers. It maintains compliance and quality programs aligned with regulatory standards and engages in patient and professional education.
Industries
Nr. of Employees
Very Large (1000+)
Products
Human albumin solutions (5%, 20%, 25%)
Purified human albumin solutions supplied in multiple concentrations and vial sizes for maintenance of circulating blood volume and as an excipient for formulations and cell culture applications.
Prothrombin complex concentrate (PCC) for warfarin reversal
Lyophilized prothrombin complex concentrate for urgent reversal of vitamin K antagonist‑induced coagulation factor deficiency in adults requiring urgent surgery or invasive procedures.
Intravenous and subcutaneous immunoglobulin formulations
IVIG and SCIG human immunoglobulin preparations for treatment of primary immunodeficiency and certain immune‑mediated conditions, supplied in multiple concentrations and presentations.
Fibrinogen concentrate and pooled plasma products
Human fibrinogen concentrate and solvent/detergent‑treated pooled plasma products intended for treatment of acquired or congenital fibrinogen deficiencies and for critical care use.
Recombinant coagulation factor VIII
Recombinant antihemophilic factor produced from human cell lines for treatment of hemophilia A across on‑demand, surgical management and prophylactic indications.
von Willebrand factor / Factor VIII complex (human)
Plasma‑derived VWF/FVIII complex indicated for treatment of von Willebrand disease and certain hemophilia A indications.
Human albumin solutions (5%, 20%, 25%)
Purified human albumin solutions supplied in multiple concentrations and vial sizes for maintenance of circulating blood volume and as an excipient for formulations and cell culture applications.
Prothrombin complex concentrate (PCC) for warfarin reversal
Lyophilized prothrombin complex concentrate for urgent reversal of vitamin K antagonist‑induced coagulation factor deficiency in adults requiring urgent surgery or invasive procedures.
Intravenous and subcutaneous immunoglobulin formulations
IVIG and SCIG human immunoglobulin preparations for treatment of primary immunodeficiency and certain immune‑mediated conditions, supplied in multiple concentrations and presentations.
Fibrinogen concentrate and pooled plasma products
Human fibrinogen concentrate and solvent/detergent‑treated pooled plasma products intended for treatment of acquired or congenital fibrinogen deficiencies and for critical care use.
Recombinant coagulation factor VIII
Recombinant antihemophilic factor produced from human cell lines for treatment of hemophilia A across on‑demand, surgical management and prophylactic indications.
von Willebrand factor / Factor VIII complex (human)
Plasma‑derived VWF/FVIII complex indicated for treatment of von Willebrand disease and certain hemophilia A indications.
Services
Provision of regulatory, technical and quality assistance to industrial customers, including supply of pharmaceutical‑grade plasma‑derived materials and documentation for manufacturing applications.
Provision of regulatory, technical and quality assistance to industrial customers, including supply of pharmaceutical‑grade plasma‑derived materials and documentation for manufacturing applications.
Expertise Areas
- Plasma fractionation and plasma‑derived therapeutics
- Recombinant protein production from human cell lines
- Clinical trial design and execution
- Regulatory compliance and quality systems (GMP, cGMP)
Key Technologies
- Plasma fractionation
- Solvent/detergent virus inactivation
- Lyophilization / freeze‑drying
- Cell culture and bioreactor production
News & Updates
Announcement of planned construction of a large manufacturing facility to expand critical care manufacturing capacity.
Multiple press releases documenting FDA approvals, label updates and orphan drug exclusivity for coagulation and immunotherapy products.
Public announcements of FDA approvals, expanded approvals, orphan drug exclusivity and emergency use authorizations for specific therapies and product presentations.
Announcement of planned construction of a large manufacturing facility to expand critical care manufacturing capacity.
Multiple press releases documenting FDA approvals, label updates and orphan drug exclusivity for coagulation and immunotherapy products.
Public announcements of FDA approvals, expanded approvals, orphan drug exclusivity and emergency use authorizations for specific therapies and product presentations.